JOURNAL ARTICLE
Use of risperidone in delirium: case reports.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists 1997 June
Traditionally, high-potency neuroleptics such as haloperidol have been used with success in the treatment of organic brain syndromes, but they have been associated with significant side effects such as EPS. We present the first case reports of a newer antipsychotic, risperidone, in the treatment of two delirious patients. Risperidone may prove to be an effective alternative to haloperidol in delirious patients, especially the elderly and the severely medically ill, who are more prone to adverse effects. Two case histories are presented, one of a 60-year-old man and the other of a 14-year-old boy in whom delirium was successfully treated with low doses of risperidone.
Full text links
Trending Papers
Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges.Antibiotics 2023 January 18
Fluid Resuscitation in Patients with Cirrhosis and Sepsis: A Multidisciplinary Perspective.Journal of Hepatology 2023 March 2
Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes.Cardiology Research 2023 Februrary
Evaluation and Management of Pulmonary Hypertension in Noncardiac Surgery: A Scientific Statement From the American Heart Association.Circulation 2023 March 17
Physical interventions to interrupt or reduce the spread of respiratory viruses.Cochrane Database of Systematic Reviews 2023 January 31
Long COVID: major findings, mechanisms and recommendations.Nature Reviews. Microbiology 2023 January 14
What's New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).Journal of Clinical Medicine 2023 Februrary 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app